NEXEL is a biotechnology company that develops and provides functional cells and safety evaluation platforms based on human iPSCs. In the NeXST program, the flagship service is the cardiac safety service, which evaluates the cardiac safety of drugs across multiple parameters using hiPSC-derived cardiomyocytes. By comprehensively analyzing electrophysiology, beating, contractility, and viability data, we support safety evaluations in an environment that closely resembles that of the human body. NeXST enables the rapid and precise evaluation of cardiac safety risks for drug candidates at an early stage
~70% Accuracy
Single Channel
Low Throughput
>87% Accuracy
Multi-Channel Effect
High-Throughput Multi-Well Plate
A case where evaluating QT/FPD prolongation and proarrhythmic risk is important.
A case demonstrating the importance of early screening for off-target cardiac liability.
NeXST supports the rapid and precise evaluation of cardiac safety risks for drug candidates at early stages.
Maestro Pro ᆞ CardioExcyte 96 ᆞ FLEXcyte 96 ᆞ AtlaZ ᆞ Mantarray ᆞ Nautilai
Cardiac Safety Assay Results - Cardiotoxicity Test Screening
(relative changes to vehicle)
The survival rate of drug development programs is very low.
Adapted from Scannell et al. 2012
Cardiotoxicity is the leading cause for drug attrition(Car, 2006)
Cardiac safety issues arise even after the drug reaches the market.
45%
of all drug withdrawals are related to cardiovascular issues
(Stevens and Baker, 2009)
NEXEL’s Cardiac Safety is the New Paradigm
ISO 9001 We have acquired and continuously renewed the international standard for quality management systems established by the International Organization for Standardization (ISO)
ISO/IEC 17025 Recognized as the international standard for evaluating the technical competence and quality management systems of testing and calibration laboratories. Test reports issued by NEXEL are recognized as having equivalent validity worldwide
ICH Participated in the domestic application of the International Council for Harmonisation (ICH) guidelines. We are contributing to the revision of shortcomings in existing arrhythmia evaluations through the ICH E14 and S7B guidelines.
CiPA Participating as the sole domestic corporate member in the Comprehensive In Vitro Proarrhythmia Assay (CiPA) initiative, contributing to the revision and improvement of experimental methods
